Business Context and Reporting Period
Company: OXIS International, Inc. (Note: Request metadata listed "GT Biopharma," but the filing text identifies the registrant as OXIS International, Inc.)
Reporting Period: Quarter and six months ended June 30, 2012.
Business Overview: OXIS is a smaller reporting company focused on the research, development, and sale of products counteracting oxidative stress and inflammation, primarily utilizing the compound L-Ergothioneine (ERGO). The company operates in dietary supplements, personal care, veterinary products, and proprietary compound licensing. As of June 30, 2012, the company had 364,299,838 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2012 | Six Months Ended June 30, 2011 |
|---|---|---|
| Total Revenue | $2,000 | $21,000 |
| Net Loss | $(3,010,000) | $(2,585,000) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.02) |
| Cash and Cash Equivalents (End of Period) | $5,000 | $89,000 |
| Net Cash Used in Operating Activities | $(495,000) | $(540,000) |
| Total Current Liabilities | $6,559,000 | $5,230,000 |
| Working Capital Deficit | $(6,450,000) | Not explicitly stated |
| Accumulated Deficit | $(86,805,000) | $(83,795,000) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $19,000 (90%) compared to the prior six-month period, dropping from $21,000 to $2,000. Management notes that revenue data is not meaningful due to a lack of active marketing.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased by $844,000 to $1,427,000. This reduction was primarily driven by a $901,000 decrease in non-cash compensation expenses compared to 2011.
- Interest Expense: Interest expense increased significantly to $1,240,000 from $348,000 in the prior period. This increase is largely attributed to a $1,120,000 settlement of claims with Bristol Investment Fund, Ltd.
- Derivative Liabilities: The company recognized a loss of $357,000 due to changes in the fair value of warrant and derivative liabilities, compared to a gain of $102,000 in the prior period.
- Debt and Equity: The company issued 95,000,000 shares of common stock during the six months ended June 30, 2012, primarily for the retirement of debt valued at $950,000. Warrant liabilities increased from $158,000 to $514,000.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's current rate of cash usage raises substantial doubt about its ability to continue as a going concern. The company has an accumulated deficit of $86.8 million and only $5,000 in cash.
- Liquidity Strategy: Management plans to raise additional capital through equity or debt financing. The company has received $682,500 from the sale of 8% convertible debentures and expects an additional $317,500 from committed investors to fund the commercial release of skin care products via a joint venture with engage:BDR, Inc.
- Product Launch: The company expects to commence online sales of its "ErgoFlex" product and other skin care lines by July 2012. However, management cannot predict the amount or timing of revenues.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2012. Material weaknesses were identified, including a lack of segregation of duties due to a small staff and risks of executive override.
- Subsequent Events: On August 8, 2012, the company entered into a settlement agreement with Bristol Investment Fund, Ltd., to resolve claims regarding convertible debentures. The settlement involves issuing restricted stock and convertible promissory notes totaling approximately $1.12 million.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to operate with only $5,000 in cash against $6.56 million in current liabilities.
- Financing Commitments: Confirm the status of the $317,500 in committed funding from investors for the engage:BDR joint venture.
- Debt Settlement: Review the terms of the August 8, 2012 settlement with Bristol Investment Fund, Ltd., specifically the issuance of new convertible notes and stock.
- Revenue Realization: Assess the feasibility of the projected revenue from the ErgoFlex and skin care product launches, given the lack of historical sales volume.
- Internal Controls: Evaluate the impact of the identified material weaknesses in internal controls on the reliability of future financial reporting.